161 related articles for article (PubMed ID: 32857918)
1. Impact of genetic alterations on outcomes of patients with stage I nonsmall cell lung cancer: An analysis of the cancer genome atlas data.
Xu S; Wang Y; Ren F; Li X; Ren D; Dong M; Chen G; Song Z; Chen J
Cancer Med; 2020 Oct; 9(20):7686-7694. PubMed ID: 32857918
[TBL] [Abstract][Full Text] [Related]
2. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
3. The Combined Detection of Immune Genes for Predicting the Prognosis of Patients With Non-Small Cell Lung Cancer.
Tian WJ; Liu SS; Li BR
Technol Cancer Res Treat; 2020; 19():1533033820977504. PubMed ID: 33256552
[TBL] [Abstract][Full Text] [Related]
4. Association of Tumor Protein p53 and Ataxia-Telangiectasia Mutated Comutation With Response to Immune Checkpoint Inhibitors and Mortality in Patients With Non-Small Cell Lung Cancer.
Chen Y; Chen G; Li J; Huang YY; Li Y; Lin J; Chen LZ; Lu JP; Wang YQ; Wang CX; Pan LK; Xia XF; Yi X; Chen CB; Zheng XW; Guo ZQ; Pan JJ
JAMA Netw Open; 2019 Sep; 2(9):e1911895. PubMed ID: 31539077
[TBL] [Abstract][Full Text] [Related]
5. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC).
Labbé C; Cabanero M; Korpanty GJ; Tomasini P; Doherty MK; Mascaux C; Jao K; Pitcher B; Wang R; Pintilie M; Leighl NB; Feld R; Liu G; Bradbury PA; Kamel-Reid S; Tsao MS; Shepherd FA
Lung Cancer; 2017 Sep; 111():23-29. PubMed ID: 28838393
[TBL] [Abstract][Full Text] [Related]
6. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
7. NKX2-1 expression as a prognostic marker in early-stage non-small-cell lung cancer.
Moisés J; Navarro A; Santasusagna S; Viñolas N; Molins L; Ramirez J; Osorio J; Saco A; Castellano JJ; Muñoz C; Morales S; Monzó M; Marrades RM
BMC Pulm Med; 2017 Dec; 17(1):197. PubMed ID: 29237428
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base.
Jiao XD; Qin BD; You P; Cai J; Zang YS
Lung Cancer; 2018 Sep; 123():70-75. PubMed ID: 30089598
[TBL] [Abstract][Full Text] [Related]
9. Mutation profiles in early-stage lung squamous cell carcinoma with clinical follow-up and correlation with markers of immune function.
Choi M; Kadara H; Zhang J; Parra ER; Rodriguez-Canales J; Gaffney SG; Zhao Z; Behrens C; Fujimoto J; Chow C; Kim K; Kalhor N; Moran C; Rimm D; Swisher S; Gibbons DL; Heymach J; Kaftan E; Townsend JP; Lynch TJ; Schlessinger J; Lee J; Lifton RP; Herbst RS; Wistuba II
Ann Oncol; 2017 Jan; 28(1):83-89. PubMed ID: 28177435
[TBL] [Abstract][Full Text] [Related]
10. Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer.
Ono A; Isaka M; Serizawa M; Omae K; Kojima H; Nakashima K; Omori S; Wakuda K; Kenmotsu H; Naito T; Murakami H; Urakami K; Nagashima T; Sugino T; Kusuhara M; Takahashi T; Yamaguchi K; Ohde Y
Lung Cancer; 2019 Feb; 128():152-157. PubMed ID: 30553548
[TBL] [Abstract][Full Text] [Related]
11. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
[TBL] [Abstract][Full Text] [Related]
12. Differential
Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
[TBL] [Abstract][Full Text] [Related]
13. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
14. Mutation patterns and evolutionary action score of TP53 enable identification of a patient population with poor prognosis in advanced non-small cell lung cancer.
Jiang W; Cheng H; Yu L; Zhang J; Wang Y; Liang Y; Lou F; Wang H; Cao S
Cancer Med; 2023 Mar; 12(6):6649-6658. PubMed ID: 36440695
[TBL] [Abstract][Full Text] [Related]
15. Prognostic effect of coexisting TP53 and ZFHX3 mutations in non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Zhang L; Zhang T; Shang B; Li Y; Cao Z; Wang H
Scand J Immunol; 2021 Sep; 94(3):e13087. PubMed ID: 35226388
[TBL] [Abstract][Full Text] [Related]
16. Mutations in TP53 increase the risk of SOX2 copy number alterations and silencing of TP53 reduces SOX2 expression in non-small cell lung cancer.
Samulin Erdem J; Skaug V; Bakke P; Gulsvik A; Haugen A; Zienolddiny S
BMC Cancer; 2016 Jan; 16():28. PubMed ID: 26780934
[TBL] [Abstract][Full Text] [Related]
17. LINE-1 hypomethylation is associated to specific clinico-pathological features in Stage I non-small cell lung cancer.
Imperatori A; Sahnane N; Rotolo N; Franzi F; Nardecchia E; Libera L; Romualdi C; Cattoni M; Sessa F; Dominioni L; Furlan D
Lung Cancer; 2017 Jun; 108():83-89. PubMed ID: 28625654
[TBL] [Abstract][Full Text] [Related]
18. The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.
Cai D; Hu C; Li L; Deng S; Yang J; Han-Zhang H; Li M
Cancer Med; 2020 Jan; 9(1):84-93. PubMed ID: 31709742
[TBL] [Abstract][Full Text] [Related]
19. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
Yang H; Wang K; Li S; Li Y; Yuan L
Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
[No Abstract] [Full Text] [Related]
20. Mutation patterns in a population-based non-small cell lung cancer cohort and prognostic impact of concomitant mutations in KRAS and TP53 or STK11.
La Fleur L; Falk-Sörqvist E; Smeds P; Berglund A; Sundström M; Mattsson JS; Brandén E; Koyi H; Isaksson J; Brunnström H; Nilsson M; Micke P; Moens L; Botling J
Lung Cancer; 2019 Apr; 130():50-58. PubMed ID: 30885352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
